212 related articles for article (PubMed ID: 29159332)
21. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
22. Activation of Focal Adhesion Kinase and Src Mediates Acquired Sorafenib Resistance in A549 Human Lung Adenocarcinoma Xenografts.
Zhou Q; Guo X; Choksi R
J Pharmacol Exp Ther; 2017 Dec; 363(3):428-443. PubMed ID: 29021381
[TBL] [Abstract][Full Text] [Related]
23. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
24. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
[TBL] [Abstract][Full Text] [Related]
25. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
[TBL] [Abstract][Full Text] [Related]
26. PEG-peptide hydrogels reveal differential effects of matrix microenvironmental cues on melanoma drug sensitivity.
Tokuda EY; Jones CE; Anseth KS
Integr Biol (Camb); 2017 Jan; 9(1):76-87. PubMed ID: 28001152
[TBL] [Abstract][Full Text] [Related]
27. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
Huang WC; Hsieh YL; Hung CM; Chien PH; Chien YF; Chen LC; Tu CY; Chen CH; Hsu SC; Lin YM; Chen YJ
PLoS One; 2013; 8(12):e83627. PubMed ID: 24391798
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
29. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
Chen JC; Chuang HY; Hsu FT; Chen YC; Chien YC; Hwang JJ
Oncotarget; 2016 Dec; 7(51):85450-85463. PubMed ID: 27863427
[TBL] [Abstract][Full Text] [Related]
32. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
Zhang QB; Sun HC; Zhang KZ; Jia QA; Bu Y; Wang M; Chai ZT; Zhang QB; Wang WQ; Kong LQ; Zhu XD; Lu L; Wu WZ; Wang L; Tang ZY
PLoS One; 2013; 8(2):e55945. PubMed ID: 23409093
[TBL] [Abstract][Full Text] [Related]
33. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.
Rudalska R; Dauch D; Longerich T; McJunkin K; Wuestefeld T; Kang TW; Hohmeyer A; Pesic M; Leibold J; von Thun A; Schirmacher P; Zuber J; Weiss KH; Powers S; Malek NP; Eilers M; Sipos B; Lowe SW; Geffers R; Laufer S; Zender L
Nat Med; 2014 Oct; 20(10):1138-46. PubMed ID: 25216638
[TBL] [Abstract][Full Text] [Related]
34. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
35. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
36. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors.
Morgillo F; Martinelli E; Troiani T; Orditura M; De Vita F; Ciardiello F
PLoS One; 2011; 6(12):e28841. PubMed ID: 22174910
[TBL] [Abstract][Full Text] [Related]
39. Induction of endoplasmic reticulum stress by sorafenib and activation of NF-κB by lestaurtinib as a novel resistance mechanism in Hodgkin lymphoma cell lines.
Holz MS; Janning A; Renné C; Gattenlöhner S; Spieker T; Bräuninger A
Mol Cancer Ther; 2013 Feb; 12(2):173-83. PubMed ID: 23243060
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.
Huynh H; Lee JW; Chow PK; Ngo VC; Lew GB; Lam IW; Ong HS; Chung A; Soo KC
Mol Cancer Ther; 2009 Jan; 8(1):152-9. PubMed ID: 19139124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
